Triggers, Drivers, and Lids: Uncovering the Mechanistic Differentiators between IL-4– and IL-13–Targeted mAbs

2025/09/26 by Karina Forde, Karina M. Forde, Alan D. Irvine · 1 voice
Immunology and Microbiology · Medicine · #Asthma and respiratory diseases #Cytokine Signaling Pathways and Interactions #Immune Response and Inflammation

paper · pdf · doi:10.1016/j.jid.2025.08.018

openalex publication_date 2025/09/26 · crossref created 2025/09/26 · openalex created_date 2025/10/10 · crossref issued 2025/12/01 · crossref published 2025/12/01 · crossref published-print 2025/12/01 · crossref deposited 2026/05/11 · crossref indexed 2026/05/11 · openalex updated_date 2026/06/21

Citations

• Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
• Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
• T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases

Discussions

• See the Commentary by Forde et al: Triggers, Drivers, and Lids: Uncovering the Mechanistic Differentiators between IL-4– and IL-13–Targeted mAbs doi.org/10.1016/j.ji... #DermatologyJournal #dermatolog [bsky, 0 points, 0 comments]